C12N 2710/16171
Demonstrated in vivo effect
C12N2710/16171 (Demonstrated in vivo effect) appears on 41 US grants and 66 published applications in this corpus.
Search patents in C12N- Granted patents
- 41
- Published applications
- 66
- Assignees
- 34
- Inventors
- 91
- Latest grant
- 14 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 1 | 0 |
| 2013 | 1 | 3 |
| 2014 | 0 | 4 |
| 2015 | 2 | 2 |
| 2016 | 3 | 5 |
| 2017 | 3 | 4 |
| 2018 | 7 | 7 |
| 2019 | 3 | 8 |
| 2020 | 5 | 4 |
| 2021 | 6 | 4 |
| 2022 | 4 | 7 |
| 2023 | 4 | 4 |
| 2024 | 0 | 3 |
| 2025 | 1 | 5 |
By publication year.
Recent patents
- Recombinant cytomegalovirus vectors as vaccines for tuberculosis14 Oct 2025US 12,442,018 B2International AIDS Vaccine Initiative
- Recombinant cytomegalovirus vectors as vaccines for tuberculosis5 Dec 2023US 11,834,669 B2International AIDS Vaccine Initiative
- Tetanus toxoid and CCL3 improve DC vaccines27 Jun 2023US 11,684,662 B2Duke University
- Vaccine compositions of herpesvirus envelope protein combinations to induce immune response7 Feb 2023US 11,572,389 B2The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Human cytomegalovirus vaccine3 Jan 2023US 11,541,113 B2ModernaTX, Inc.
- Immunotherapeutic compositions for treatment of glioblastoma multiforme18 Dec 2025US 2025/0381266 A1Variation Biotechnologies Inc.
- Human cytomegalovirus vaccine17 Jul 2025US 2025/0228932 A1ModernaTX, Inc.
- Poxvirus-based vectors produced by natural or synthetic dna and uses thereof3 Jul 2025US 2025/0215456 A1City of Hope
- Immunogenic compositions and uses thereof1 May 2025US 2025/0134990 A1The Council of the Queensland Institute of Medical Research
- Human cytomegalovirus rna vaccines13 Mar 2025US 2025/0082748 A1ModernaTX, Inc.
Most cited
By later US patents
- Human cytomegalovirus RNA vaccines130US 10,064,935 B2ModernaTX, Inc. · 2018
- Human cytomegalovirus vaccine80US 10,695,419 B2ModernaTX, Inc. · 2020
- Human cytomegalovirus vaccine44US 11,406,703 B2ModernaTX, Inc. · 2022
- Recombinant HCMV and RHCMV vectors and uses thereof20US 9,249,427 B2Oregon Health & Science University · 2016
- Pharmaceutical compositions containing 1-methyl-D-tryptophan14US 8,232,313 B2Georgia Health Sciences University · 2012